PENNINGTON BIOMEDICAL RESEARCH CENTER
BATON ROUGE, LOUISIANA
INSTITUTIONAL BIOSAFETY COMMITTEE

Dr. Diana Coulon
Dr. Prachi Singh
Dr. Timothy Heden
Dr. Abigail Fish (Non-Voting Member)
Dr. Jason Collier, Chair
Dr. Krisztian Stadler, Vice-Chair
Dr. Leonard Ezell, Community Representative
Jennifer Strickland, Community Representative
Dr. Christopher Morrison, Responsible Official
Dr. Stefany Primeaux
Dr. Erik Westin
Dr. Christy White
Dr. Sangho Yu

MEETING MINUTES

Thursday, September 10th, 2026
2:00 PM – B2001

Institution	Pennington Biomedical Research Center Baton Rouge, LA
Meeting Date	Thursday, September 10th, 2026
Meeting Time	2:02 PM – 2:52 PM
Meeting Type	In person meeting
IBC Members Present	1. Dr. Krisztian Stadler, (Chair) 2. Dr. Stefany Primeaux, (Vice Chair) 3. Dr. Christy White (Safety Officer) 4. Dr. Diana Coulon (Animal expert) 5. Dr. Timothy Heden 6. Dr. Sangho Yu 7. Dr. Prachi Singh

Dr. Diana Coulon
Dr. Prachi Singh
Dr. Timothy Heden
Dr. Abigail Fish (Non-Voting Member)
Dr. Jason Collier, Chair
Dr. Krisztian Stadler, Vice-Chair
Dr. Leonard Ezell, Community Representative
Jennifer Strickland, Community Representative
Dr. Christopher Morrison, Responsible Official
Dr. Stefany Primeaux
Dr. Erik Westin
Dr. Christy White
Dr. Sangho Yu

	8. Jennifer Strickland (Community Non-affiliated Member) 9. Sujoy Ghosh
IBC Members Absent	1. Abigail Fish (Non-Voting Member) 2. Dr. Erik Westin 3. Leonard Ezell (Community Non-affiliated Member)
Quorum	Present
Other Individuals in Attendance	N/A
Call to Order	2:02 PM
Conflicts of Interest	*The IBC Chair reminded all members present to identify any conflicts of interest as each registration is reviewed.*
Review and approval of previous meeting minutes	July 2026 Motion: Dr. Sangho Yu Second: Dr. Prachi Singh

Dr. Diana Coulon
Dr. Prachi Singh
Dr. Timothy Heden
Dr. Abigail Fish (Non-Voting Member)
Dr. Jason Collier, Chair
Dr. Krisztian Stadler, Vice-Chair
Dr. Leonard Ezell, Community Representative
Jennifer Strickland, Community Representative
Dr. Christopher Morrison, Responsible Official
Dr. Stefany Primeaux
Dr. Erik Westin
Dr. Christy White
Dr. Sangho Yu

	All in Favor 8/8
Review of Prior Business	Waiting for modifications to be completed by Allerton Lab for R2602 SCULPT.

New IBC Registrations and Amendments for Review	
PI Name(s)	Greenway, Frank PhD
Registration Number/Title	Registration Renewal: R2607 Translational research using human cell cultures
Project Overview	The Human Obesity lab conducts translational studies to analyze effects of natural compounds on human cells and cell lines. Their hypothesis is that natural compounds can be combined to enhance their efficacy for the treatment of obesity, diabetes, polycystic ovary syndrome and cancer. They also collaborate with pharmaceutical companies to study synthetic compounds that act on these diseases.

Dr. Diana Coulon
Dr. Prachi Singh
Dr. Timothy Heden
Dr. Abigail Fish (Non-Voting Member)
Dr. Jason Collier, Chair
Dr. Krisztian Stadler, Vice-Chair
Dr. Leonard Ezell, Community Representative
Jennifer Strickland, Community Representative
Dr. Christopher Morrison, Responsible Official
Dr. Stefany Primeaux
Dr. Erik Westin
Dr. Christy White
Dr. Sangho Yu

NIH Guidelines Section	N/A
Risk Assessment and Discussion	From human tissues and cell lines, there are risks of blood borne pathogens, in particular viruses such as hepatitis and HIV (AIDS) that are serious health risks. Any exposure of skin (wounds) or eyes can be infectious. Some hepatitis viruses can survive on dry surfaces for days and care must be taken to decontaminate any surface that had contact. HIV can be contracted by exposure to contaminated blood through open sores or needle sticks. All staff receive required biosafety and safety training, use appropriate personal protective equipment and follow proper procedures for handling and disposing of samples and sharps. All human samples and cell lines are treated as potentially infectious. Employees who may be exposed to human fluids or cell lines are also offered the Hepatitis B vaccine.
Training	All required training courses are complete for all lab staff listed in the registration.
Occupational Health Representative review (if applicable):	All staff has received bloodborne pathogen training and has received or formally declined the hepatitis B vaccine.
Biosafety Level Assignment	BSL-2

Dr. Diana Coulon
Dr. Prachi Singh
Dr. Timothy Heden
Dr. Abigail Fish (Non-Voting Member)
Dr. Jason Collier, Chair
Dr. Krisztian Stadler, Vice-Chair
Dr. Leonard Ezell, Community Representative
Jennifer Strickland, Community Representative
Dr. Christopher Morrison, Responsible Official
Dr. Stefany Primeaux
Dr. Erik Westin
Dr. Christy White
Dr. Sangho Yu

IBC Vote	A motion was made and seconded to approve the registration pending changes or conditions to be met. All in favor 9/9 Conflicts of Interest: None
Modifications Requested	1. Remove all references to chemical hazards (organic solvents, sodium azide and doxorubicin) as that information does not belong in this registration. 2. Clearly state that all human tissues, blood samples, primary cells, and human cell lines will be handled using BSL-2 safety practices and treated as potentially infectious. 3. Ensure that all surfaces wiped with bleach are followed by 70% ethanol. 4. State that samples will be spun in a centrifuge with a sealed rotor to reduce the risk of aerosols. 5. Clearly label boxes that are used to transport cell cultures and human fat tissue as biohazardous and include appropriate lab information. 6. Add that stock supplies will be inventoried at least once a year.

Dr. Diana Coulon
Dr. Prachi Singh
Dr. Timothy Heden
Dr. Abigail Fish (Non-Voting Member)
Dr. Jason Collier, Chair
Dr. Krisztian Stadler, Vice-Chair
Dr. Leonard Ezell, Community Representative
Jennifer Strickland, Community Representative
Dr. Christopher Morrison, Responsible Official
Dr. Stefany Primeaux
Dr. Erik Westin
Dr. Christy White
Dr. Sangho Yu

PI Name(s)	Collier, Jason PhD
Registration Number/Title	Registration Renewal: R2608 Inflammation in Pancreatic Islets
Project Overview	The pancreatic beta cell is the only cell that makes and secretes insulin. Without insulin, people become diabetic. The lab studies how the only cell that makes and secretes insulin (beta cell) functions normally and becomes dysfunctional in situations such as autoimmunity and obesity. Towards this goal, they use recombinant DNA from commercial sources and standard laboratory-based procedures delivered to rodent and human cell lines and isolated pancreatic islets. These experiments reflect an effort to determine how to protect against losses in the function and total number of insulin producing cells. Their goal is to limit the disease process(es) that lead to both major forms of diabetes mellitus (Type 1 and Type 2).
NIH Guidelines Section	*Section III-D-3-a*
Risk Assessment and Discussion	The adenoviruses used in these experiments are specially designed so they cannot normally reproduce or become part of a cell's DNA, making them less likely to cause genetic changes or illness. Although extremely rare, these viruses could regain the ability to reproduce, so all virus samples are tested regularly. Viruses are tested for E1A and any virus that shows signs of being able to reproduce is discarded as biohazard waste after proper decontamination. All work involving these viruses is performed using BSL-2 safety procedures, and researchers are protected by PPE, training and engineering controls.

Dr. Diana Coulon
Dr. Prachi Singh
Dr. Timothy Heden
Dr. Abigail Fish (Non-Voting Member)
Dr. Jason Collier, Chair
Dr. Krisztian Stadler, Vice-Chair
Dr. Leonard Ezell, Community Representative
Jennifer Strickland, Community Representative
Dr. Christopher Morrison, Responsible Official
Dr. Stefany Primeaux
Dr. Erik Westin
Dr. Christy White
Dr. Sangho Yu

	Working with human tissues may involve exposure to viruses such as HIV, hepatitis, and COVID-19. Proper protective equipment, careful handling, and sterile techniques help reduce this risk. All samples are handled as potentially infectious materials.
Training	All required training courses are complete for all lab staff listed in the registration.
Occupational Health Representative review (if applicable):	All staff has received bloodborne pathogen training and has received or formally declined the hepatitis B vaccine.
Biosafety Level Assignment	BSL-2, BL1N
IBC Vote	A motion was made and seconded to approve the registration pending changes or conditions to be met. All in favor 9/9 Conflicts of Interest: None
Modifications Requested	1. Clarify that liquid waste is not being thrown away in the Stericycle biohazard waste bins. 2. Clarify the strain of E. Coli being used and add this work to the experimental procedures. 3. Add the pancreatic islets and remove the mouse and rat cell lines from the human or primate blood and tissue section. 4. Remove the outdated SOP and specify that SOPs will be reviewed annually with staff. 5. Update the NIH Guideline reference to III-D-3-a because the work involves E1A. 6. State that centrifuges will have biohazard warning symbols displayed on them. 7. Add a reference to the CBC Escaped Rodent Policy.

Dr. Diana Coulon
Dr. Prachi Singh
Dr. Timothy Heden
Dr. Abigail Fish (Non-Voting Member)
Dr. Jason Collier, Chair
Dr. Krisztian Stadler, Vice-Chair
Dr. Leonard Ezell, Community Representative
Jennifer Strickland, Community Representative
Dr. Christopher Morrison, Responsible Official
Dr. Stefany Primeaux
Dr. Erik Westin
Dr. Christy White
Dr. Sangho Yu

PI Name(s)	Kesterson, Robert PhD
Registration Number/Title	Registration Amendment: R2602 Targeted disruption of genes in murine models related to traditional NF1-related tumors using STEP-Cas9 or STEP-Cre
Project Overview	The original registration included: We propose to inject STEP-Cre into the flank near the sciatic nerve of the mouse or into targeted structures in the brain (subventricular zone, striatum or cortical parenchyma, hippocampus, or via intracerebroventricular injection (ICV), as examples) for the purposes of generating peripheral nerve sheath tumors or gliomas, respectively. The amendment adds both intrathecal (IT) and intraductal (ID) injections into mice. The injections will also be performed in a biosafety cabinet with volumes will range from 10-20uL with a total dosing ranging from 100ug-500ug.
NIH Guidelines Section	*N/A*

Dr. Diana Coulon
Dr. Prachi Singh
Dr. Timothy Heden
Dr. Abigail Fish (Non-Voting Member)
Dr. Jason Collier, Chair
Dr. Krisztian Stadler, Vice-Chair
Dr. Leonard Ezell, Community Representative
Jennifer Strickland, Community Representative
Dr. Christopher Morrison, Responsible Official
Dr. Stefany Primeaux
Dr. Erik Westin
Dr. Christy White
Dr. Sangho Yu

Risk Assessment and Discussion	There is no change in risk due to the change in injection locations
Training	All required training courses are complete for all lab staff listed in the registration.
Occupational Health Representative review (if applicable):	N/A
Biosafety Level Assignment	BSL-2. ABSL-1
IBC Vote	A motion was made and seconded to approve the registration pending changes or conditions to be met. All in favor 9/9 Conflicts of Interest: None
Modifications Requested	1. In the "Please assess the change in risk" section, reword the first sentence as it is weirdly written.
Other Business	
	1. The Committee looked over and discussed the new "Review Policy for high-risk life science research," and discussed the role that the IBC will be expected to take.

Dr. Diana Coulon
Dr. Prachi Singh
Dr. Timothy Heden
Dr. Abigail Fish (Non-Voting Member)
Dr. Jason Collier, Chair
Dr. Krisztian Stadler, Vice-Chair
Dr. Leonard Ezell, Community Representative
Jennifer Strickland, Community Representative
Dr. Christopher Morrison, Responsible Official
Dr. Stefany Primeaux
Dr. Erik Westin
Dr. Christy White
Dr. Sangho Yu

	2. The Committee looked over and discussed the Draft NIH Biosafety Policy for Research Involving Biohazards. The comment period lasts until October 19th , and the committee plans to submit a comment from the committee.
	The IBC Chair moved to adjourn the meeting at 2:52 PM. Next Month's Meeting will be scheduled for October 8th at 2 pm.